Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

NCT03426254 PHASE1 WITHDRAWN

To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose

Details

Lead sponsor	Center Trials & Treatment
Phase	PHASE1
Status	WITHDRAWN
Start date	Thu Nov 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jan 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced or Recurrent Solid Tumors
• Breast Neoplasm

Interventions

• Injections Subcutaneously Talazoparib
• Oral capsules Talazoparib

Countries

Albania